FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised.
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
PHILADELPHIA, October 24, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food and Drug Administration...
GSK presents positive data for AREXVY, its respiratory syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain underlying medical conditions.
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in …
Feb 6, 2024 · If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is currently approved in the US...
RSV Vaccine Arexvy Approved for Adults Aged 50 to 59 Years at …
Jun 11, 2024 · The FDA has approved Arexvy for the prevention of RSV-LRTD in adults 50 through 59 years of age who are at increased risk for RSV disease.
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, …
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
AREXVY | FDA - U.S. Food and Drug Administration
Jun 2, 2023 · For active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older.